ERBB2 and gastric cancer: The CheckMate 649 study was a Phase 3 trial that compared nivolumab plus chemotherapy (XELOX/FOLFOX) with chemotherapy alone as the first-line treatment in patients with HER2-negative advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma.